Zinc Supplementation With Botulinum Toxin for Overactive Bladder

Inclusion Criteria: * Non-pregnant adult female at least 21 years old, with no plans to become pregnant during the course of the trial) and if of child-bearing potential, with a negative pregnancy test, and if sexually active, must be using medically acceptable contraception. * ≥ 6 urgency urinary incontinence episodes on a 3-day baseline bladder diary, with these urge incontinence episodes representing greater than 50% of the total incontinent episodes recorded. * Willing and able to complete all study related items and interviews. * Refractory urgency urinary incontinence: defined as persistent symptoms despite at least one or more conservative treatments (e.g. supervised behavioral therapy, supervised physical therapy) * Persistent symptoms despite the use of a minimum of two anticholinergics, or unable to tolerate medication due to side effects, or has a contraindication to taking anticholinergic/Beta 3 agonist medication. * Currently not on an anticholinergic or antimuscarinic/Beta 3 agonist medication (e.g. oxybutynin, tolterodine, darifenacin, trospium chloride, solifenacin-succinate, fesoterodine and/or mirabegron) or be willing to stop medication for 3 weeks prior to completing baseline bladder diary and expected to remain off medications through duration of study. * Demonstrates ability (or have caregiver demonstrate ability) to perform clean intermittent self-catheterization. * Grossly neurologically normal on exam and no gross systemic neurologic conditions believed to affect urinary function. Exclusion Criteria: * Neurologic diseases such as multiple sclerosis, Parkinson Disease, CVA within 6 months prior to enrollment, myasthenia gravis, Charcot-Marie-Tooth disease, clinically significant peripheral neuropathy, and complete spinal cord injury. * Untreated urinary tract infection (UTI). * Any prior use of either study therapy for treatment of urinary urge incontinence (Botox A® or Interstim®). * PVR \>150 ml on 2 occasions within 6 months prior to enrollment (If the PVR value was obtained by ultrasound and was ≥150 ml, the PVR will be confirmed by catheterization which will be the gold standard). * Current or prior bladder malignancy. * Surgically altered detrusor muscle, such as augmentation cystoplasty. * Subjects taking aminoglycosides. * Currently pregnant or lactating. * Allergy to lidocaine or bupivacaine. * Prior pelvic radiation. * Uninvestigated hematuria.